0 Ratings

ID

45978

Description

Principal Investigator: Patricia L. Hibberd, Division of Global Health, Massachusetts General Hospital for Children, Boston, MA, USA MeSH: Human Microbiome https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000896 A mechanistic understanding of the health benefits conferred by consumption of probiotic bacteria has been limited by our knowledge of the resident gut microbiota and its interaction with the host. We used fecal samples from a study of twelve healthy individuals aged 65-80 to characterize the structure and functional dynamics of the gut microbiota associated with consumption of the single-organism probiotic, Lactobacillus rhamnosus GG ATCC 53103 (LGG). Samples were collected prior to probiotic consumption (day 0), on day 28 immediately after consuming 10^10 CFU of LGG twice daily for 28 days and day 56, one month after stopping LGG consumption. Our integrative approach incorporated bacterial 16S rRNA gene sequencing, whole-community expression profiling using RNA-seq, and metagenomic sequencing. We highlight the value of combinatorial 'omics methods and concomitant high-resolution informatics to probe the role that probiotics may play on the structure and function of the resident microbiota.

Link

dbGaP study=phs000896

Keywords

  1. 4/2/24 4/2/24 - Madita Rudolph
Copyright Holder

Patricia L. Hibberd, Division of Global Health, Massachusetts General Hospital for Children, Boston, MA, USA

Uploaded on

April 2, 2024

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :


    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    dbGaP phs000896 Functional Dynamics of the Elderly Gut Microbiome During Probiotic Consumption

    Eligibility Criteria

    Inclusion and exclusion criteria
    Description

    Inclusion and exclusion criteria

    Alias
    UMLS CUI [1,1]
    C1512693
    UMLS CUI [1,2]
    C0680251
    See also doi:10.1371/journal.pone.0113456.t001 <th>Inclusion Criteria</th> <th>Exclusion Criteria</th> 1. Adult male and female age 65--80 years 1. Resident of a nursing home or rehabilitation center 2. Has a primary care physician 2. Hospitalization, major surgery or endoscopy within the last 3 months or scheduled hospital admission within 3 months of enrollment 3. In the past two years: 3. Consumption of any probiotic or yogurt that has the "live and active cultures" seal during the 28 days before the baseline visit and unwillingness to forgo these products during the 56 day study period a. Is community-dwelling 4. Received oral or parenteral antibiotics during the 28 days before the baseline visit b. Has had a routine physical examination 5. Current or planned oral or parenteral immunosuppressive therapy, chemotherapy or radiotherapy c. Has no new chronic conditions diagnosed 6. Allergy to probiotics, Lactobacillus, all antibiotics that could be used to treat Lactobacillus infection, microcrystaline cellulose or gelatin 4. Has received and is up to date on the following: 7. Diarrhea, constipation or vomiting during the 28 days before the baseline visit a. Pneumococcal vaccination 8. Serious gastrointestinal illness including chronic liver disease, gastrointestinal surgery, cancer, inflammatory bowel disease, pancreatitis or motility disorder in the last 2 years b. Mammography (women only) 9. History of drug or alcohol abuse in the previous 12 months c. Screening colonoscopy 10. History of structural heart disease, endocarditis, valve replacement, Stage IV congestive heart failure, peripheral vascular disease, stroke, chronic obstructive pulmonary disease, asthma, collagen, vascular or autoimmune disease, end stage renal disease, diabetes, thyroid disease or active tuberculosis 5. Willing and able to comply with the protocol and participate for the planned duration of the study 11. Presence of an indwelling catheter, implanted hardware/prosthetic device or feeding tube 6. Completes the informed consent process 12. Any Grade 2 or higher abnormal vital sign or physical examination finding (FDA Toxicity Grading Scale) 13. Positive HIV antibody, hepatitis B surface antigen or hepatitis C antibody 14. Positive urine toxicology or positive breathalyzer 15. Any Grade 2 or higher abnormal screening laboratory test (FDA Toxicity Grading Scale) 16. Enrolled in another study
    Description

    Elig.phs000896.v1.p1.1

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C1516637
    UMLS CUI [1,2]
    C2348563
    UMLS CUI [1,3]
    C3846158

    Similar models

    Eligibility Criteria

    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    Inclusion and exclusion criteria
    C1512693 (UMLS CUI [1,1])
    C0680251 (UMLS CUI [1,2])
    Elig.phs000896.v1.p1.1
    Item
    See also doi:10.1371/journal.pone.0113456.t001 <th>Inclusion Criteria</th> <th>Exclusion Criteria</th> 1. Adult male and female age 65--80 years 1. Resident of a nursing home or rehabilitation center 2. Has a primary care physician 2. Hospitalization, major surgery or endoscopy within the last 3 months or scheduled hospital admission within 3 months of enrollment 3. In the past two years: 3. Consumption of any probiotic or yogurt that has the "live and active cultures" seal during the 28 days before the baseline visit and unwillingness to forgo these products during the 56 day study period a. Is community-dwelling 4. Received oral or parenteral antibiotics during the 28 days before the baseline visit b. Has had a routine physical examination 5. Current or planned oral or parenteral immunosuppressive therapy, chemotherapy or radiotherapy c. Has no new chronic conditions diagnosed 6. Allergy to probiotics, Lactobacillus, all antibiotics that could be used to treat Lactobacillus infection, microcrystaline cellulose or gelatin 4. Has received and is up to date on the following: 7. Diarrhea, constipation or vomiting during the 28 days before the baseline visit a. Pneumococcal vaccination 8. Serious gastrointestinal illness including chronic liver disease, gastrointestinal surgery, cancer, inflammatory bowel disease, pancreatitis or motility disorder in the last 2 years b. Mammography (women only) 9. History of drug or alcohol abuse in the previous 12 months c. Screening colonoscopy 10. History of structural heart disease, endocarditis, valve replacement, Stage IV congestive heart failure, peripheral vascular disease, stroke, chronic obstructive pulmonary disease, asthma, collagen, vascular or autoimmune disease, end stage renal disease, diabetes, thyroid disease or active tuberculosis 5. Willing and able to comply with the protocol and participate for the planned duration of the study 11. Presence of an indwelling catheter, implanted hardware/prosthetic device or feeding tube 6. Completes the informed consent process 12. Any Grade 2 or higher abnormal vital sign or physical examination finding (FDA Toxicity Grading Scale) 13. Positive HIV antibody, hepatitis B surface antigen or hepatitis C antibody 14. Positive urine toxicology or positive breathalyzer 15. Any Grade 2 or higher abnormal screening laboratory test (FDA Toxicity Grading Scale) 16. Enrolled in another study
    boolean
    C1516637 (UMLS CUI [1,1])
    C2348563 (UMLS CUI [1,2])
    C3846158 (UMLS CUI [1,3])

    Please use this form for feedback, questions and suggestions for improvements.

    Fields marked with * are required.

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial